NCT03765476 is a NA clinical trial of SALIENCE in Alcohol Use Disorder, sponsored by Central Institute of Mental Health, Mannheim.

Who is sponsoring NCT03765476?

NCT03765476 is sponsored by Central Institute of Mental Health, Mannheim.

What drugs are being tested in NCT03765476?

Interventions in NCT03765476: SALIENCE, TAU.

What condition does NCT03765476 study?

NCT03765476 studies Alcohol Use Disorder.

Is NCT03765476 still recruiting?

NCT03765476 is currently active, enrolled. Last updated 29 April 2025.

Last reviewed 2025-04-29 · How we verify

NCT03765476

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of a Training Program for Patients With Alcohol Use Disorder

Active, enrolled NA Last updated 29 April 2025

What this trial tests

NA trial testing SALIENCE in Alcohol Use Disorder in 125 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 July 2018

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Central Institute of Mental Health, Mannheim
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	125
Start date	1 July 2018
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across Germany

Drugs / interventions tested

SALIENCE
TAU — full drug profile →

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →

Sponsor

Central Institute of Mental Health, Mannheim

Who can join

Adults 18 to 65, any sex, with Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to detect how the Web-based program SALIENCE affects patients with alcohol-use Disorder in terms of craving, cognitive functions and risk of relapse.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effectiveness of Reducing Craving in Alcohol Use Disorder Using a Serious Game (SALIENCE): Randomized Controlled Trial.
Weber A, Shevchenko Y, Gerhardt S, Hoffmann S, et al · · 2023 · cited 2× · PMID 37934561 · DOI 10.2196/42194

Verify or expand the search:

Other trials of SALIENCE

Trials testing the same drug.

NCT03460574 — Targeting Cognitive Immunization in Depression · NA · completed

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other Central Institute of Mental Health, Mannheim trials

Trials by the same sponsor.

NCT06845124 — A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence · Phase 2 · recruiting
NCT00916201 — Evaluation Study of New Compounds With Potential Use in Schizophrenia · Phase 1 · withdrawn
NCT06959342 — Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treat · NA · recruiting
NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
NCT05726045 — Increasing Smoking Cessation Success Through Sleep-amplified Memory Consolidation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03765476 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Institute of Mental Health, Mannheim
Last refreshed: 29 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03765476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing